N2 PHARMACEUTICALS LTD

N2 PHARMACEUTICALS LTD is rated 3 out of 5 in the category biotechnology. Read and write reviews about N2 PHARMACEUTICALS LTD. SMART Scotland Grant winners Animal Health Investment Europe showcase finalists - London 2018 Informa Disruptors & innovators report 2018 Top 20 Animal Health start-ups N2 Pharmaceuticals has developed N2-01, a unique injectable medicine extracted from meat of Blue mussels. It has already been registered for veterinary use in Russia in 2010 under the leadership of the current CEO. N2-01 has proven, both in laboratory settings and during its usage on animals, to reduce the level of endothelial dysfunction. The medicine proved to be effective in numerous conditions related to endothelial dysfunction, when used on more than 25,000 companion and food producing animals by practicing veterinarians: • Improvement of quality of life in palliative care of cats and dogs (mainly late stages of cancer and multimorbidity associated with old age) • Acute and chronic kidney failure (cats and dogs) • As a supportive treatment during tick-borne diseases (dogs). The drug does not affect the parasites, but supports the animal during toxic treatment of the disease • Improvement of the effectiveness of artificial insemination in dairy cattle through reduction of early embryonic mortality. • Increases survival rate and improves recovery during/after the most invasive surgeries (dogs, cats) N2-Pharmaceuticals is based at Roslin Innovation Centre in Edinburgh and is currently working on the compound's registration with the European Medical Agency. The technology has numerous patents in the UK, EU, USA and Russia.